Heron Therapeutics Inc Stock Price, News & Analysis

Heron Therapeutics (Nasdaq: HRTX) announced the submission of a New Drug Application (NDA) for HTX-019, an injectable emulsion of aprepitant aimed at preventing postoperative nausea and vomiting (PONV) in adults. The NDA includes data supporting the bioequivalence of HTX-019 32 mg IV injection to 40 mg oral aprepitant. This formulation offers faster and more reliable drug exposure, addressing the significant unmet need for effective PONV prevention. Aprepitant is the only NK1 receptor antagonist approved for this indication, with potential benefits for millions of surgical patients annually.

Heron Therapeutics (Nasdaq: HRTX) announced its participation in upcoming investor conferences, focusing on enhancing patient care through innovative treatments. At the Jefferies London Healthcare Conference on November 18-19, 2021, a fireside chat will be available on-demand. Additionally, during the 4th Annual Evercore ISI HealthCONx Conference from November 30 - December 2, 2021, a live fireside chat is scheduled for December 1 at 2:40 PM ET. Webcasts of these events can be accessed via the Company's website.

Heron Therapeutics reported Q3 2021 financial results, with net product sales of $23.2 million, a rise from $20.0 million in Q3 2020. The company achieved $65.7 million in net sales for the nine months ended September 30, 2021, compared to $68.0 million the prior year. ZYNRELEF, launched July 2021, generated $2.1 million in sales, with strong formulary approvals. Despite a net loss of $52.4 million for Q3 2021, down from $58.2 million in Q3 2020, cash reserves were $202.8 million as of September 30, 2021. Future guidance suggests moderated cash usage and potential sales growth in 2022.

Heron Therapeutics (Nasdaq: HRTX) will host a conference call on November 3, 2021, at 4:15 p.m. ET to discuss their third quarter 2021 financial results and recent business highlights. The call is accessible via phone for domestic and international callers and will also be available as a webcast on Heron's website. An archive will be provided for 60 days. Heron focuses on developing innovative treatments to meet unmet patient needs in acute care and oncology.

Heron Therapeutics, Inc. (Nasdaq: HRTX) submitted a supplemental New Drug Application (NDA) to the FDA for its product ZYNRELEF, expanding its indication to include foot and ankle, small-to-medium open abdominal, and lower extremity joint surgeries without the need for additional studies. This followed a successful Type C meeting with the FDA, which allows for two sequential NDA submissions. The company aims to significantly increase the number of indicated procedures, targeting up to 14 million surgeries. ZYNRELEF is the first extended-release local anesthetic approved for postoperative pain management.

Heron Therapeutics, Inc. (Nasdaq: HRTX) announced that Barry Quart, CEO, and John Poyhonen, President, will engage in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference. The event is scheduled for September 27, 2021, at 1:20 pm ET. A live webcast will be accessible via the company's website, with a replay available for 60 days post-event. Heron Therapeutics focuses on developing advanced treatments to meet significant unmet patient needs in acute care and oncology. For further details, visit www.herontx.com.

Heron Therapeutics (HRTX) reported financial results for Q2 and H1 2021, highlighting a net loss of $61 million and $113.6 million, respectively. Net product sales for oncology care amounted to $22.4 million in Q2, slightly down from $22.7 million a year prior. ZYNRELEF, a new product launched in July 2021, saw positive early adoption with 61 unique accounts placing orders. However, the company faces challenges in growth projections due to reduced cancer patient treatments amid the pandemic and increased competition. Cash reserves stand at $257.7 million, reflecting a strategic preparation for product launches.

Heron Therapeutics, Inc. (Nasdaq: HRTX) announced the publication of HOPE Hernia-1 study results for ZYNRELEF in hernia repair surgery. The study demonstrates over 90% of patients discharged without opioid prescriptions and 95% recovering opioid-free, showcasing ZYNRELEF's role in non-opioid multimodal analgesia. ZYNRELEF is an extended-release formulation of bupivacaine and meloxicam, approved for postsurgical analgesia. The findings emphasize ZYNRELEF’s potential to minimize opioid use, pivotal in addressing the opioid crisis.

Heron Therapeutics (HRTX) announced the online publication of a new analysis in the journal Pain Management, evaluating the effectiveness of ZYNRELEF (bupivacaine and meloxicam) in adults 65 years and older after bunionectomy and hernia repair. The analysis revealed that 58% of bunionectomy and 87% of hernia repair patients did not require opioids post-surgery. ZYNRELEF was well tolerated, showing a similar safety profile to bupivacaine, with no serious adverse events related to the medication. This positions ZYNRELEF as a significant improvement over standard opioid treatments.